Narrative Review of Emerging Roles for AKT-mTOR Signaling in Cancer Radioimmunotherapy

Overview

Journal Ann Transl Med

Publisher AME Publishing Company

Date 2021 Nov 18

PMID 34790802

Citations 6

Authors

Changxian Shen

Yuqi He

Qiang Chen

Haihua Feng

Terence M Williams

Yuanzhi Lu

Zhengfu He

Affiliations

Soon will be listed here.

Abstract

Objective: To summarize the roles of AKT-mTOR signaling in the regulation of the DNA damage response and PD-L1 expression in cancer cells, and propose a novel strategy of targeting AKT-mTOR signaling in combination with radioimmunotherapy in the era of cancer immunotherapy.

Background: Immunotherapy has greatly improved the clinical outcomes of many cancer patients and has changed the landscape of cancer patient management. However, only a small subgroup of cancer patients (~20-30%) benefit from immune checkpoint blockade-based immunotherapy. The current challenge is to find biomarkers to predict the response of patients to immunotherapy and strategies to sensitize patients to immunotherapy.

Methods: Search and review the literature which were published in PUBMED from 2000-2021 with the key words mTOR, AKT, drug resistance, DNA damage response, immunotherapy, PD-L1, DNA repair, radioimmunotherapy.

Conclusions: More than 50% of cancer patients receive radiotherapy during their course of treatment. Radiotherapy has been shown to reduce the growth of locally irradiated tumors as well as metastatic non-irradiated tumors (abscopal effects) by affecting systemic immunity. Consistently, immunotherapy has been demonstrated to enhance radiotherapy with more than one hundred clinical trials of radiation in combination with immunotherapy (radioimmunotherapy) across cancer types. Nevertheless, current available data have shown limited efficacy of trials testing radioimmunotherapy. AKT-mTOR signaling is a major tumor growth-promoting pathway and is upregulated in most cancers. AKT-mTOR signaling is activated by growth factors as well as genotoxic stresses including radiotherapy. Importantly, recent advances have shown that AKT-mTOR is one of the main signaling pathways that regulate DNA damage repair as well as PD-L1 levels in cancers. These recent advances clearly suggest a novel cancer therapy strategy by targeting AKT-mTOR signaling in combination with radioimmunotherapy.

Citing Articles

Immune escape and metastasis mechanisms in melanoma: breaking down the dichotomy.

Shirley C, Chhabra G, Amiri D, Chang H, Ahmad N Front Immunol. 2024; 15:1336023.

PMID: 38426087 PMC: 10902921. DOI: 10.3389/fimmu.2024.1336023.

IFN-γ decreases PD-1 in T lymphocytes from convalescent COVID-19 patients via the AKT/GSK3β signaling pathway.

Song M, Liu X, Shen W, Wang Z, Wu J, Jiang J Sci Rep. 2024; 14(1):5038.

PMID: 38424104 PMC: 10904811. DOI: 10.1038/s41598-024-55191-6.

Pharmacological effect and mechanism of orlistat in anti-tumor therapy: A review.

Hao X, Zhu X, Tian H, Lai G, Zhang W, Zhou H Medicine (Baltimore). 2023; 102(36):e34671.

PMID: 37682175 PMC: 10489489. DOI: 10.1097/MD.0000000000034671.

A phase 1 evaluation of the safety and tolerability of niraparib in combination with everolimus in advanced ovarian and breast cancers.

Starks D, Rojas-Espaillat L, Meissner T, Elsey R, Xu B, Koenen M Cancer Med. 2023; 12(18):18654-18665.

PMID: 37644890 PMC: 10557865. DOI: 10.1002/cam4.6475.

Epigallocatechin Gallate Relieved PM2.5-Induced Lung Fibrosis by Inhibiting Oxidative Damage and Epithelial-Mesenchymal Transition through AKT/mTOR Pathway.

Zhongyin Z, Wei W, Juan X, Guohua F Oxid Med Cell Longev. 2022; 2022:7291774.

PMID: 35707275 PMC: 9192191. DOI: 10.1155/2022/7291774.

References

Chaudhury I, Sareen A, Raghunandan M, Sobeck A . FANCD2 regulates BLM complex functions independently of FANCI to promote replication fork recovery. Nucleic Acids Res. 2013; 41(13):6444-59. PMC: 3711430. DOI: 10.1093/nar/gkt348. View

Liu P, Cheng H, Roberts T, Zhao J . Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009; 8(8):627-44. PMC: 3142564. DOI: 10.1038/nrd2926. View

Fingar D, Richardson C, Tee A, Cheatham L, Tsou C, Blenis J . mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol. 2003; 24(1):200-16. PMC: 303352. DOI: 10.1128/MCB.24.1.200-216.2004. View

Galluzzi L, Humeau J, Buque A, Zitvogel L, Kroemer G . Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020; 17(12):725-741. DOI: 10.1038/s41571-020-0413-z. View

Sun S . Searching for the real function of mTOR signaling in the regulation of PD-L1 expression. Transl Oncol. 2020; 13(12):100847. PMC: 7451686. DOI: 10.1016/j.tranon.2020.100847. View

Wang X, Hawk N, Yue P, Kauh J, Ramalingam S, Fu H . Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy. Cancer Biol Ther. 2008; 7(12):1952-8. PMC: 2762753. DOI: 10.4161/cbt.7.12.6944. View

Desrichard A, Snyder A, Chan T . Cancer Neoantigens and Applications for Immunotherapy. Clin Cancer Res. 2015; 22(4):807-12. DOI: 10.1158/1078-0432.CCR-14-3175. View

Lamberti G, Sisi M, Andrini E, Palladini A, Giunchi F, Lollini P . The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?. Cancers (Basel). 2020; 12(11). PMC: 7692442. DOI: 10.3390/cancers12113129. View

Sumimoto H, Takano A, Teramoto K, Daigo Y . RAS-Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers. PLoS One. 2016; 11(11):e0166626. PMC: 5112979. DOI: 10.1371/journal.pone.0166626. View

10.

Caporali S, Levati L, Starace G, Ragone G, Bonmassar E, Alvino E . AKT is activated in an ataxia-telangiectasia and Rad3-related-dependent manner in response to temozolomide and confers protection against drug-induced cell growth inhibition. Mol Pharmacol. 2008; 74(1):173-83. DOI: 10.1124/mol.107.044743. View

11.

Guo F, Li J, Du W, Zhang S, OConnor M, Thomas G . mTOR regulates DNA damage response through NF-κB-mediated FANCD2 pathway in hematopoietic cells. Leukemia. 2013; 27(10):2040-2046. PMC: 4225699. DOI: 10.1038/leu.2013.93. View

12.

Zhou X, Liu W, Hu X, Dorrance A, Garzon R, Houghton P . Regulation of CHK1 by mTOR contributes to the evasion of DNA damage barrier of cancer cells. Sci Rep. 2017; 7(1):1535. PMC: 5431544. DOI: 10.1038/s41598-017-01729-w. View

13.

Meric-Bernstam F, Gonzalez-Angulo A . Targeting the mTOR signaling network for cancer therapy. J Clin Oncol. 2009; 27(13):2278-87. PMC: 2738634. DOI: 10.1200/JCO.2008.20.0766. View

14.

Oka K, Ohya-Shimada W, Mizuno S, Nakamura T . Up-regulation of cyclin-E(1) via proline-mTOR pathway is responsible for HGF-mediated G(1)/S progression in the primary culture of rat hepatocytes. Biochem Biophys Res Commun. 2013; 435(1):120-5. DOI: 10.1016/j.bbrc.2013.04.052. View

15.

Ferguson F, Gray N . Kinase inhibitors: the road ahead. Nat Rev Drug Discov. 2018; 17(5):353-377. DOI: 10.1038/nrd.2018.21. View

16.

Xie J, Proud C . Crosstalk between mTOR complexes. Nat Cell Biol. 2013; 15(11):1263-5. DOI: 10.1038/ncb2877. View

17.

Lastwika K, Wilson 3rd W, Li Q, Norris J, Xu H, Ghazarian S . Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer. Cancer Res. 2015; 76(2):227-38. DOI: 10.1158/0008-5472.CAN-14-3362. View

18.

Knipscheer P, Raschle M, Smogorzewska A, Enoiu M, Ho T, Scharer O . The Fanconi anemia pathway promotes replication-dependent DNA interstrand cross-link repair. Science. 2009; 326(5960):1698-701. PMC: 2909596. DOI: 10.1126/science.1182372. View

19.

Federico M, Campodonico P, Paviolo N, Gottifredi V . Beyond interstrand crosslinks repair: contribution of FANCD2 and other Fanconi Anemia proteins to the replication of DNA. Mutat Res. 2017; 808:83-92. DOI: 10.1016/j.mrfmmm.2017.09.004. View

20.

Vitale I, Sistigu A, Manic G, Rudqvist N, Trajanoski Z, Galluzzi L . Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy. Trends Cell Biol. 2019; 29(5):396-416. DOI: 10.1016/j.tcb.2019.01.003. View